DITRA is a dubious disease in the field of autoimmune and rheumatic immunity, with complex clinical outcomes and often involving multi-system complications. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of therapeutically oriented, immune-regulatory therapies and precision medicine, many previously difficult to treat autoimmune and rheumatic immune disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changing conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of DITRA-associated epileptic thrombosis. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2.
Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3. Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.